Leerink Swann Cuts PT on Amicus Therapeutics (FOLD), But Remains Overall Bullilsh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Wedbush Downgrades Amicus Therapeutics (FOLD) to Underperform, Sees Another 50% Slide
December 21, 2012 9:39 AM ESTAmicus Therapeutics (NASDAQ: FOLD) fell 47 percent on Thursday after its ongoing migalastat monotherapy Phase III trial did not meet the primary and a pre-defined secondary endpoint, however, one analyst thinks it goes down another 50 percent from here.
Wedbush downgraded Amicus from Neutral to... More
Amicus Therapeutics (FOLD), Glaxo (GSK) Report Study 011 Did Not Achieve Primary Endpoint
December 19, 2012 4:12 PM ESTAmicus Therapeutics (Nasdaq: FOLD) and GlaxoSmithKline plc (NYSE: GSK) announced the 6-month primary treatment period results from the first Phase 3 global registration study (Study 011) of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had genetic mutations identified as amenable to migalastat HCl in a cell-based assay. Study 011 randomized a total of 67 patients to receive oral migalastat HCl 150 mg or placebo on an every-other-day (QOD) dosing schedule during a 6-month, double-blind primary treatment period.
Reduction of GL-3 Substrate in Kidney Interstitial Capillaries:
... More
